Elevation Oncology to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Elevation Oncology, Inc. (Nasdaq: ELEV) will present a corporate overview and engage in one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. An on-demand replay of the presentation will be available starting November 22, 2021, at 10:00 am ET on their Investor Relations website. The company focuses on precision medicines for genomically defined cancers, with lead candidate seribantumab targeting NRG1 fusions in a Phase 2 study. For more details, visit their official site.
- None.
- None.
NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that members of the senior management team will present a corporate overview and participate in one-on-one investor meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference, taking place November 29, 2021 to December 2, 2021.
An on-demand replay of the presentation can be accessed beginning November 22, 2021 at 10:00 am ET on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor's unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion. Details on CRESTONE are available at www.NRG1fusion.com. For more information visit www.ElevationOncology.com.
Elevation Oncology Investor and Media Contact
Candice Masse, 978-879-7273
Senior Director, Corporate Communications & Investor Relations
cmasse@elevationoncology.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-piper-sandler-33rd-annual-virtual-healthcare-conference-301427298.html
SOURCE Elevation Oncology
FAQ
When is Elevation Oncology presenting at the Piper Sandler conference?
How can I access the Elevation Oncology presentation replay?
What is the focus of Elevation Oncology?
What is seribantumab and its significance?
Where can I find more information about Elevation Oncology?
